Accessibility StatementSkip Navigation PHILADELPHIA, Nov. 12, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) ("Telix" or the "Company") on behalf of investors who purchased Telix securities during the period of February 21, 2025 through August 28, 2025 (the "Class Period"). Investor Deadline: Investors who purchased Telix securities during the Class Period may, no later than Januar ...

Core Viewpoint - Firefly Aerospace Inc. is facing a class action lawsuit due to alleged violations of securities laws, with claims that the company misrepresented its business prospects and financial performance during its IPO and subsequent reporting period [1][4][5]. Company Overview - Firefly Aerospace operates in the space and defense technology sector, providing mission solutions for national security, government, and commercial customers [3]. IPO Details - The company conducted its initial public offering (IPO) on August 7, 2025, issuing approximately 19.3 million shares at an offering price of $45.00 per share [3]. Allegations of Misrepresentation - The lawsuit alleges that Firefly Aerospace overstated demand and growth prospects for its Spacecraft Solutions offerings, as well as the operational readiness and commercial viability of its Alpha rocket program [4]. Financial Performance - In its first earnings report as a public company on September 22, 2025, Firefly Aerospace reported a loss of $80.3 million for Q2 2025, compared to a loss of $58.7 million in Q2 2024. Revenue was reported at $15.55 million, below analyst estimates of $17.25 million, and down 26.2% year-over-year [5]. - The Spacecraft Solutions business segment reported revenue of only $9.2 million, representing a 49% year-over-year decrease [5]. Stock Price Impact - Following the earnings report, Firefly Aerospace's stock price fell more than 15%. Additionally, on September 29, 2025, the company disclosed an issue with its Alpha Flight 7 rocket, leading to a further decline of over 20% in its stock price [5][6].

Core Viewpoint - Investors in James Hardie Industries plc have the opportunity to lead a securities fraud class action lawsuit due to alleged misleading statements regarding the company's sales and inventory practices [1][2]. Group 1: Lawsuit Details - The lawsuit claims that from May 20, 2025, to August 18, 2025, James Hardie failed to disclose that its largest business segment was experiencing inventory loading by channel partners, resembling fraudulent channel stuffing, rather than sustainable customer demand [2]. - The complaint asserts that the positive statements made by the defendants about the company's business, operations, and prospects were materially misleading and lacked a reasonable basis during the relevant period [2]. Group 2: Participation Information - Investors who suffered losses related to James Hardie are encouraged to participate in the ongoing securities fraud lawsuit before the lead plaintiff deadline of December 23, 2025 [2]. - Interested parties can contact the Law Offices of Frank R. Cruz for more information or to learn about their rights regarding the lawsuit [3][4].

Core Viewpoint - The Portnoy Law Firm has initiated an investigation into potential securities fraud involving Soleno Therapeutics, Inc. and may file a class action lawsuit on behalf of investors [1][2]. Company Developments - On March 26, 2025, Soleno Therapeutics announced FDA approval for VYKAT XR (diazoxide choline) extended-release tablets aimed at treating hyperphagia in individuals with Prader-Willi syndrome aged 4 and older [3]. - During a quarterly earnings call on November 4, 2025, Soleno disclosed that the discontinuation rate for VYKAT XR due to adverse effects was approximately 8% by the end of Q3 fiscal 2025 [3]. - CEO Anish Bhatnagar acknowledged a disruption in the launch trajectory of VYKAT XR following a short seller report released in mid-August, which resulted in a decrease in start forms and an increase in discontinuations for non-serious adverse events [3]. - Following these developments, Soleno's share price experienced a decline of over 26% [3].

LOS ANGELES, Nov. 12, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises HelloFresh SE, (“HelloFresh" or the "Company") (OTC: HELFY, HLFFF) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.  Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal rights, or join the case via https://portnoylaw.com/hellofresh-SE. The Portnoy Law Firm ...

Core Points - Savers Value Village, Inc. is under investigation for possible violations of federal securities laws following its recent financial disclosures [1][2] - The company conducted its IPO on June 29, 2023, offering 25,635,415 shares at $18.00 per share [2] - In its third-quarter financial results reported on October 30, 2025, Savers posted a non-GAAP profit of $0.14 per share, but a GAAP loss of $0.09 per share, leading to a stock price drop of over 30% on October 31, 2025 [2] Company Background - Levi & Korsinsky LLP is a recognized securities litigation firm with a history of securing significant settlements for shareholders and has a team of over 70 employees [3] - The firm has been ranked in the Top 50 Report by ISS Securities Class Action Services for seven consecutive years, highlighting its expertise in complex securities litigation [3]

Group 1 - A class action securities lawsuit has been filed against Avantor, Inc. to recover losses for shareholders affected by alleged securities fraud between March 5, 2024, and October 28, 2025 [2][3] - The complaint alleges that Avantor's competitive positioning was misrepresented, indicating it was weaker than publicly stated, and that the company faced negative impacts from increased competition [3] - Defendants are accused of making materially false and misleading statements regarding the company's business operations and future prospects [3] Group 2 - Shareholders who suffered losses during the specified timeframe are encouraged to learn about their rights to seek recovery, with no cost or obligation to participate [4] - Levi & Korsinsky LLP is highlighted as a nationally-recognized securities litigation firm with a strong track record in securing recoveries for shareholders [5]

New York, New York--(Newsfile Corp. - November 12, 2025) - If you suffered a loss on your Inspire Medical Systems, Inc. (NYSE: INSP) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:https://zlk.com/pslra-1/inspire-medical-systems-inc-lawsuit-submission-form?prid=176930&wire=5&utm_campaign=3or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareho ...

Core Viewpoint - A class action lawsuit has been filed against James Hardie Industries plc for securities fraud, following a significant stock drop attributed to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - Investors have until December 23, 2025, to request to lead the case in the U.S. District Court for the Northern District of Illinois [3]. - The lawsuit claims violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in James Hardie common stock [3]. Group 2: Company Background - James Hardie is a producer and marketer of high-performance fiber cement building solutions, primarily used in external siding for the residential building industry in the U.S. and Canada [4]. Group 3: Allegations of Fraud - During the relevant period, James Hardie misrepresented the strength and momentum of its North American fiber cement segment, claiming sustainable customer demand when, in fact, sales were driven by inventory loading by channel partners [5]. - The company reported a 12% decline in North American fiber cement sales during the quarter, revealing that customers were destocking to return to normal inventory levels [6]. Group 4: Stock Impact - Following the revelation of declining sales, James Hardie's stock price fell by $9.79 per share, a decrease of over 34%, from $28.43 on August 19, 2025, to $18.64 on August 20, 2025 [6].

KMX SHAREHOLDER ALERT: BFA Law Notifies CarMax, Inc. Investors of Important January 2 Securities Class Action Deadline for Investors seeking RecoveryNovember 12, 2025 7:17 AM EST | Source: Bleichmar Fonti & AuldNew York, New York--(Newsfile Corp. - November 12, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against CarMax, Inc. (NYSE: KMX) and certain of the Company's senior executives for securities fraud after a significant ...